Drugs / CPI-1205
CPI-1205
also known as
EZH2 INHIBITOR CPI-1205 · GTPL9115 · LIRAMETOSTAT · LIRAMETOSTAT (CPI-1205) · SCHEMBL17329268
Small molecule targets EZH2 via inhibition
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03525795 | Dec 2017 → Jun 2019 | cancer | Constellation Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02395601 | Mar 2015 → Dec 2018 | B-cell neoplasm | Constellation Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03480646 | Nov 2017 → Feb 2021 | castration-resistant prostate carcinoma | Constellation Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CPI-1205 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03480646 ↗ |
| Known as | EZH2 INHIBITOR CPI-1205 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297463 ↗ |
| Known as | GTPL9115 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297463 ↗ |
| Known as | LIRAMETOSTAT | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297463 ↗ |
| Known as | LIRAMETOSTAT (CPI-1205) | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297463 ↗ |
| Known as | SCHEMBL17329268 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297463 ↗ |
| Action | Inhibit | “CPI-1205 is a small molecule inhibitor of EZH2.” NCT02395601 ↗ |
| Modality | Small molecule | “CPI-1205 is a small molecule inhibitor of EZH2.” NCT02395601 ↗ |
| Route | Oral | “CPI-1205 was administered orally TID or BID (as of Amendment 2).” NCT03480646 ↗ |
| Target | EZH2 | “CPI-1205 is a small molecule inhibitor of EZH2.” NCT02395601 ↗ |